# US 2011/0257241 A1 · 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257241 A1
- Document ID: US20110257241A1
- Status: Published application
- Kind: A1
- Application number: 13/130,438
- Filed: 2009-11-24
- Published: 2011-10-20
- Earliest claimed: 2008-11-24
- Assignees: Nsab, Filial Af Neurosearch Sweden AB, Sverige
- Inventors: Clas Sonesson; Lars Swanson; Fredrik Pettersson
- Web page: https://patentgrep.com/patent/US20110257241A1

## CPC

- C07D 207/12: Oxygen or sulfur atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/04: for inducing labour or abortion; Uterotonics
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.

## Claims

### Claim 1

A 3-phenyl-3-methoxy-pyrrolidine derivative of Formula 1:
any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, wherein
R1 is F or Cl;
R2 is F or Cl; and
R3 is H, CH3 or CH2CH3;
with the proviso that the compound is not 3-(2,4-Difluorophenyl)-3-methoxypyrrolidine.

### Claim 2 (depends on 1)

The 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, wherein R1 is F or Cl.

### Claim 3 (depends on 1)

The 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, wherein R2 is F or Cl.

### Claim 4 (depends on 1)

The 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, wherein R3 is H, CH3 or CH2CH3, or a deuterated analog thereof.

### Claim 5 (depends on 1)

The 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, which is
(+)-3-(3-Chloro-2-fluorophenyl)-3-methoxypyrrolidine;
(+)-3-(3-Chloro-2-fluorophenyl)-1-ethyl-3-methoxypyrrolidine;
(−)-3-(3-Chloro-2-fluorophenyl)-3-methoxypyrrolidine;
(−)-3-(3-Chloro-2-fluorophenyl)-1-ethyl-3-methoxypyrrolidine;
(+)-3-(2,3-Difluorophenyl)-3-methoxypyrrolidine;
(+)-3-(2,3-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
(+3-(2,3-Difluorophenyl)-3-methoxypynolidine;
(−)-3-(2,3-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
3-(3 ,4-Difluorophenyl)-3-methoxypyrrolidine;
3-(3,4-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
3-(3-Chloro-5-fluorophenyl)-3-methoxypyrrolidine;
3-(2,3-Difluorophenyl)-3-methoxypyrrolidine;
3-(2,3-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
(+)-3-(3,5-Difluorophenyl)-3-methoxypyrrolidine;
(+3-(3,5-Difluorophenyl)-3-methoxypyrrolidine,
Enantiomer 1 of 3-(3,5-Difluorophenyl)-3-methoxy-1-methyl pyrrolidine;
Enantiomer 2 of 3-(3,5-Difluorophenyl)-3-methoxy-1-methyl pyrrolidine;
Enantiomer 1 of 3-(3,5-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3,5-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
(+)-3-(3,4-Difluorophenyl)-3-methoxypyrrolidine;
(−)-3-(3 ,4-Difluorophenyl)-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-1-(ethyl-D5)-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-(1-D)-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-3-methoxy-l-methylpyrrolidine;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-3-methoxy-1-(methyl-D3)-pyrrolidine;
Enantiomer 1 of 3-(3,4-Difluorophenyl)-3-methoxy-1-(methyl-D3)-pyrrolidine;
Enantiomer 1 of 3-(3,4-Difluorophenyl)-(1-D)-3-methoxypyrrolidine;
Enantiomer 1 of 3-(3,4-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 1 of 3-(3,4-Difluorophenyl)-1-(ethyl-D5)-3-methoxypyrrolidine;
Enantiomer 1 of 3-(3,4-Difluorophenyl)-3-methoxy-1-methylpyrrolidine;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine-1-oxide;
Enantiomer 2 of 3-(3,4-Difluorophenyl)-1-(ethyl-D5)-3-methoxypyrrolidine-1-oxide;
Enantiomer 2 of 3-(3 ,4-Difluorophenyl)-3-methoxy-1-methylpyrrolidine-1-oxide;
Enantiomer 2 of 3-(3 ,4-Difluorophenyl)-3-methoxy-1-(methyl-D3)-pyrrolidine-1-oxide;
Enantiomer 1 of 3-(3 ,4-Difluorophenyl)-3-methoxy-1-(methyl-D3)-pyrrolidine-1-oxide;
Enantiomer 1 of 3-(3 ,4-Difluorophenyl)-1-ethyl-3-methoxypyrrolidine-1-oxide;
Enantiomer 1 of 3-(3 ,4-Difluorophenyl)-1-(ethyl-D5)-3-methoxypyrrolidine-1-oxide;
Enantiomer 1 of 3-(3 ,4-Difluorophenyl)-3-methoxy-1-methylpyrrolidine-1-oxide;
(+)-3-(3-Chloro-5-fluorophenyl)-3-methoxypyrrolidine;
(−)-3-(3-Chloro-5-fluorophenyl)-3-methoxypyrrolidine;
(+)-3-(3-Chloro-4-fluorophenyl)-3-methoxypyrrolidine;
(−)-3-(3-Chloro-4-fluorophenyl)-3-methoxypyrrolidine;
Enantiomer 1 of 3-(3-Chloro-5-fluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3-Chloro-5-fluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 1 of 3-(3-Chloro-4-fluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 2 of 3-(3-Chloro-4-fluorophenyl)-1-ethyl-3-methoxypyrrolidine;
Enantiomer 1 of 3-(3-Chloro-2-fluorophenyl)-(1-D)-3-methoxypyrrolidine;
Enantiomer 1 of 3 -(3-Chloro-4-fluorophenyl)-(1-D)-3-methoxypyrrolidine; or
Enantiomer 2 of 3-(3-Chloro-4-fluorophenyl)-(1-D)-3-methoxypyrrolidine;
any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a 3-phenyl-3-methoxy-pyrrolidine derivative of claim 1, any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 10)

The method according to claim 10, wherein the disease, disorder or condition is dementia, age-related cognitive impairment, Autism spectrum disorders, ADHD, Cerebral Palsy, Huntington's disease, Gilles de la Tourette's syndrome, depression, bipolar disorder, schizophrenia, schizophreniform disorders, generalized anxiety disorder (GAD), specific phobias, panic disorder, sleep disorders, bipolar disorders, drug induced psychotic disorders, iatrogenic psychoses, Iatrogenic hallucinoses, non-iatrogenic psychoses, non-iatrogenic hallucinoses, mood disorders, anxiety disorders, depression, obsessive-compulsive disease, emotional disturbances related to ageing, Alzheimer's disease, dementia, dementia disorders related to Alzheimer's disease, age-related cognitive impairment, brain injury, substance abuse, disorders characterized by misuse of food, sleep disorders, sexual disorders, eating disorders, obesitas, headaches, pains in conditions characterized by increased muscular tone, movement disorders, Parkinson's disease, Parkinsonism, parkinsonian syndromes, dyskinesias, L-DOPA induced dyskinesias, dystonias, neurodevelopmental disorders, neurodegenerative disorders, tics, tremor, restless legs, narcolepsy or behavioural disorders.

### Claim 10 (depends on 1)

A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to modulation of catecholamines in the cerebral cortex, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, or any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, for use as a medicament.

### Claim 12 (depends on 1)

A 3-phenyl-3-methoxy-pyrrolidine derivative according to claim 1, any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a deuterated analog thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to responsive to modulation of catecholamines in the cerebral cortex.
